New Sensors Lower the Cost of Studying Genetic Disorders 

Demonstration of a new class with low-cost sensors can help to scale the use of monitoring electrical activity in human cerebral organoids, as electrical signals are key to understanding the functioning of the brain, and this advancement facilitates research into both neurodevelopment and genetic disorders such as Angelman syndrome. 

Human cerebral organoids are millimetre-sized tissues comprised of cell types typically found in the different regions of the brain. They are made by culturing stem cells. These organoids are important to many fields of research because they allow researchers to study the behaviour of nervous system cells and tissues in ways that are not possible with animal models. 

According to Towards Healthcare, the in-vitro and in-vivo micro electrode array market is projected to experience significant growth, with estimates suggesting the market size will increase from USD 1.47 billion in 2026 to approximately USD 3.17 billion by 2035, representing a compound annual growth rate (CAGR) of 8.9% from 2026 to 2035. Growth is driven by the development of high-density microelectrode arrays and integration with AI for real-time data analysis, are revolutionizing research methodologies and enhancing the efficacy of neurotransmission studies. 

 Mishra also stated, however, that the sensors currently used in organoid research are expensive, due to both the materials they are made from and the manufacturing process itself, which places financial constraints that result in researchers often using fewer than 10 organoids for a given study. 

About CAMEO 

The device consists of 12 carbon nanotube strands suspended in the shape of a basket. The carbon nanotubes are processed in a way that preserves the material’s flexibility and sensitivity to electrical signals. In practice, the organoid is suspended in the CAMEO, like an egg in a basket. The end of each strand is exposed, creating an electrode that can detect electrical signals from the organoid. The signals are then transmitted through the carbon nanotube strand to a device that can record electrical activity. 

Technological advancements, such as the development of high-density microelectrode arrays and integration with AI for real-time data analysis, are revolutionising research methodologies and enhancing the efficacy of neurotransmission studies. 

A recent report by Towards Healthcare highlights that the in-vitro and in-vivo micro electrode array market is witnessing growth due to the integration of artificial intelligence and machine learning algorithms with microelectrode data, enhancing diagnostic accuracy and therapeutic efficacy, further fueling market expansion. Regulatory approvals and funding initiatives also serve as significant demand catalysts. Governments and research institutions worldwide are increasing investments in neuroscience research, fostering a conducive environment for market growth.